Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Problem-, resources- and goals-oriented (PRoGO) approach in psychiatry: illustrated by the case of Ludwig II of Bavaria.

European archives of psychiatry and clinical neuroscience·2026
Same author

Dementia Care Research and Psychosocial Factors.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Clinical Manifestations.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Relationship between efficacy and preferential targeting of soluble Aβ aggregates.

Alzheimer's & dementia (New York, N. Y.)·2025
Same journal

Advances in the Application of Brain-Computer Interface-Based Neurofeedback Training in the Rehabilitation of Patients with Major Depressive Disorder.

Neuropsychiatric disease and treatment·2026
Same journal

Second-Generation Long-Acting Injectable Antipsychotics: A Comprehensive Assessment of Effectiveness, Safety, and Cost.

Neuropsychiatric disease and treatment·2026
Same journal

Resting-State EEG Characteristics of Tardive Dyskinesia: Spectral and Network Connectivity Insights.

Neuropsychiatric disease and treatment·2026
Same journal

Efficacy of Adjunctive Lumateperone 42 mg on Anhedonia and Across a Broad Range of Depressive Symptoms in Major Depressive Disorder: Post Hoc Analysis of a Phase 3, Randomized, Placebo-Controlled Trial.

Neuropsychiatric disease and treatment·2026
Same journal

Modifying Neuropsychiatric and Motor Trajectories in Huntington's Disease Through an Integrated Neurobehavioral Clinic Model.

Neuropsychiatric disease and treatment·2026
Same journal

Mini-Review: Allicin as a Potential Neuroprotective Compound in Neurological Disorders.

Neuropsychiatric disease and treatment·2026
See all related articles

Related Experiment Video

Updated: May 2, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.2K

Frontotemporal lobar degeneration: current perspectives.

Lina Riedl1, Ian R Mackenzie2, Hans Förstl1

  • 1Center for Cognitive Disorders, Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

Neuropsychiatric Disease and Treatment
|March 7, 2014
PubMed
Summary
This summary is machine-generated.

Frontotemporal lobar degeneration (FTLD) is a group of brain diseases affecting frontal and temporal lobes, often before age 60. Diagnosis is challenging, with no specific cure, making caregiver support crucial.

Keywords:
frontotemporal dementiafrontotemporal lobar degenerationreview

More Related Videos

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
08:33

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

6.9K
Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
09:33

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Published on: July 28, 2013

27.9K

Related Experiment Videos

Last Updated: May 2, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.2K
Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
08:33

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

6.9K
Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
09:33

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Published on: July 28, 2013

27.9K

Area of Science:

  • Neurology
  • Neuroscience
  • Genetics

Background:

  • Frontotemporal lobar degeneration (FTLD) encompasses progressive brain diseases impacting frontal and temporal lobes.
  • Clinical presentations vary, including behavioral changes or language impairments, typically before age 60.
  • FTLD prevalence is comparable to Alzheimer's disease in the 45-65 age group.

Purpose of the Study:

  • To review the clinical and pathological characteristics of FTLD.
  • To highlight diagnostic challenges and current treatment limitations.
  • To emphasize the importance of caregiver support in FTLD management.

Main Methods:

  • Review of clinical subtypes: behavioral-variant FTD and primary progressive aphasia.
  • Discussion of neuropathological hallmarks, including protein aggregates (MAPT, TDP, FUS).
  • Examination of genetic factors, such as mutations in MAPT, GRN, and C9orf72, in familial FTLD.

Main Results:

  • FTLD diagnosis remains challenging despite advances in biomarkers and imaging.
  • Current treatments are limited, with some evidence for SSRIs in managing behavioral symptoms.
  • No definitive large-scale studies support non-pharmacological interventions.

Conclusions:

  • Caregiver education and support are paramount in managing FTLD due to limited therapeutic options.
  • Further research is needed to develop effective treatments for FTLD.
  • Understanding the heterogeneous nature of FTLD is key for accurate diagnosis and management.